Sisram Medical (1696) investor relations material

Executive summary

• Revenue grew 4.7% year-over-year to $365.3 million, driven by strong APAC and international expansion, especially in China and Thailand, offsetting North America declines.

• Injectables revenue surged 185.6% to $28 million, led by Profhilo in Thailand and DAXXIFY launches, with direct sales expansion in APAC.

• Gross profit margin declined to 58.9%, impacted by geographic/product mix and new import tariffs.

• Adjusted net profit rose 7.9% to $31 million, with margin up to 8.5%; reported net profit declined 13.1% to $25 million due to one-time gains in 2024.

• Expanded product ecosystem integrating EBD, injectables, diagnostics, and AI-enabled solutions, positioning for long-term industry trends.

Financial highlights

• Revenue reached $365.3 million (+4.7% YoY); international markets (ex-North America) grew 20.1%.

• APAC revenue rose 26.9% to $147.4 million; North America revenue declined 19.2% to $111 million.

• EBD revenue was $310.4 million (85% of total), flat year-on-year; injectables revenue surged 185.6% to $28 million.

• Gross profit was $215.1 million with a gross margin of 58.9%, down from 62.1% in 2024.

• Adjusted net profit was $31 million, up 7.9% year-on-year, with an 8.5% adjusted net margin.

Outlook and guidance

• Plans to launch new EBD platforms and expand injectables, including DAXXIFY commercialization in China and Profhilo launch by 2027.

• Focus on operational efficiency, cost management, and continued investment in R&D, AI integration, and digitalization.

• Expects macroeconomic improvement in North America and continued APAC growth; maintains cautious optimism amid geopolitical risks.

• Pursuing M&A opportunities to strengthen R&D and portfolio depth.

• Localized production in China to enhance supply chain resilience.